Skip to main content
This section contains press releases and other materials from third parties (including paid content). The Globe and Mail has not reviewed this content. Please see disclaimer.

Analysts’ Opinions Are Mixed on These Healthcare Stocks: IDEAYA Biosciences (IDYA), BioNTech SE (BNTX) and Stryker (SYK)

Tipranks - Tipranks - Tue Apr 14, 7:22AM CDT

Analysts have been eager to weigh in on the Healthcare sector with new ratings on IDEAYA Biosciences (IDYA), BioNTech SE (BNTX) and Stryker (SYK).

Claim 30% Off TipRanks

IDEAYA Biosciences (IDYA)

In a report released today, Gregory Renza from Truist Financial maintained a Buy rating on IDEAYA Biosciences. The company’s shares closed last Friday at $30.50.

According to TipRanks.com, Renza is a 5-star analyst with an average return of 17.8% and a 46.4% success rate. Renza covers the Healthcare sector, focusing on stocks such as Ascentage Pharma Group International Unsponsored ADR, Perspective Therapeutics, and Abivax SA Sponsored ADR. ;'>

IDEAYA Biosciences has an analyst consensus of Strong Buy, with a price target consensus of $54.80, a 77.3% upside from current levels. In a report issued on March 31, Mizuho Securities also reiterated a Buy rating on the stock with a $46.00 price target.

See Insiders’ Hot Stocks on TipRanks >>

BioNTech SE (BNTX)

In a report released today, Harry Gillis from Berenberg Bank maintained a Buy rating on BioNTech SE, with a price target of $155.00. The company’s shares closed last Friday at $95.50.

According to TipRanks.com, Gillis is a 2-star analyst with an average return of 1.1% and a 36.4% success rate. Gillis covers the Healthcare sector, focusing on stocks such as Atai Beckley N.V., Tecan Group AG, and Moderna. ;'>

BioNTech SE has an analyst consensus of Strong Buy, with a price target consensus of $136.81, implying a 47.5% upside from current levels. In a report issued on April 10, Morgan Stanley also maintained a Buy rating on the stock with a $126.00 price target.

Stryker (SYK)

In a report released today, Richard Newitter from Truist Financial maintained a Hold rating on Stryker. The company’s shares closed last Friday at $339.15.

According to TipRanks.com, Newitter is a 4-star analyst with an average return of 7.7% and a 47.0% success rate. Newitter covers the Healthcare sector, focusing on stocks such as Treace Medical Concepts, Inspire Medical Systems, and Zimmer Biomet Holdings. ;'>

Stryker has an analyst consensus of Strong Buy, with a price target consensus of $425.10, a 24.0% upside from current levels. In a report issued on April 9, Goldman Sachs also assigned a Hold rating to the stock with a $357.00 price target.

Read More on IDYA:

Disclaimer & DisclosureReport an Issue

This article contains syndicated content. We have not reviewed, approved, or endorsed the content, and may receive compensation for placement of the content on this site. For more information please view the Barchart Disclosure Policy here.

All market data (will open in new tab) is provided by Barchart Solutions. Copyright © 2026.

Information is provided 'as is' and solely for informational purposes, not for trading purposes or advice. For exchange delays and terms of use, please read disclaimer (will open in new tab).